Axsome Therapeutics, Inc AXSM

The Motley Fool 14 nov

Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.

The Motley Fool 11 nov

Following a 5% Nasdaq decline after midterm elections, the article recommends two stocks for long-term investors: Shopify, which is leveraging AI-powered tools to drive strong revenue growth and capitalize on e-commerce expansion, and Axsome Therapeutics, a biotech company with strong performance from its depression and Alzheimer's drug Auvelity and a promising pipeline of new products.

Zacks Investment Research 2 nov

Axsome Therapeutics (AXSM) reported a quarterly loss of $0.25 per share, beating consensus estimates of $0.69 loss by 63.77%, with revenues of $259.69 million exceeding expectations by 5.37%. However, the stock has underperformed the market, declining 20.9% year-to-date versus the S&P 500's 10.7% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

The Motley Fool 28 oct

Axsome Therapeutics has demonstrated steady quarter-over-quarter revenue growth, surpassing Moderna's quarterly revenue by Q2 2026 despite starting from a much smaller base. Meanwhile, Moderna has experienced significant revenue volatility, with sharp declines following peaks, largely due to reduced COVID-19 vaccine adoption and underperforming RSV vaccine sales. Axsome's three-drug portfolio shows promise with multiple clinical trials underway, while Moderna faces challenges from overreliance on products that have lost market traction.

Zacks Investment Research 27 oct

Rhythm Pharmaceuticals (RYTM) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +1.38% and Zacks Rank #3. The company is projected to report a quarterly loss of $0.68 per share (improved from $0.81 year-ago) with revenues of $84.47 million, up 64.7% year-over-year. The stock has beaten consensus EPS estimates in 3 of the last 4 quarters.